{"id":1002899,"date":"2026-09-11T08:14:51","date_gmt":"2026-09-11T12:14:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/"},"modified":"2026-09-11T08:14:51","modified_gmt":"2026-09-11T12:14:51","slug":"glucotrack-announces-11-5-million-financing","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/","title":{"rendered":"Glucotrack Announces $11.5 Million Financing"},"content":{"rendered":"<p>        <!--body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p><b>Glucotrack Announces $11.5 Million Financing<\/b><\/p>\n<p>RUTHERFORD, N.J. &amp; LA JOLLA, Calif.&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nGlucotrack, Inc. (NASDAQ: GCTK) (\u201cGlucotrack\u201d or the \u201cCompany\u201d) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount. The financing is structured as convertible debt with an initial conversion price of $3.12 per share. In connection with the financing, investors will also receive warrants exercisable at $7.50 per share.<\/p>\n<p>\nDawson James Securities, Inc. acted as Sole Placement Agent for Glucotrack.<\/p>\n<p><b>About Glucotrack, Inc.<\/b><\/p>\n<p>\nGlucotrack, Inc. (NASDAQ: GCTK) operates L\u014dkahi and, through its subsidiary Glucotrack Technologies, Inc., is also focused on the design, development, and commercialization of novel technologies for people with diabetes, including a long-term implantable continuous blood glucose monitoring system. The Glucotrack CBGM is an Investigational Device and is limited by federal (or United States) law to investigational use. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.glucotrack.com___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDozYmFmZDQ1YzkyNWFlMDQxNzkxYzFlNjU1ODliMjljNjo3OjVjYjk6ZjgxYjBhMzhiYTk4YzY2YjIzMzkyYmQzZDQ2MDJlYzUwMzg2NzJiZDQ5MWFlZjVlN2QwZjllNmU3ZDViYzdiOTpwOkY6Rg&amp;esheet=54602003&amp;newsitemid=20260911828722&amp;lan=en-US&amp;anchor=www.glucotrack.com&amp;index=1&amp;md5=8557a1bef98bf5e2bb4b95ce1184af90\">www.glucotrack.com<\/a>.<\/p>\n<p><b>About L\u014dkahi Therapeutics\u2122<\/b><\/p>\n<p>\nL\u014dkahi Therapeutics is a capital-efficient biopharmaceutical platform company focused on identifying, evaluating, 9196026557, and advancing overlooked therapeutic assets. Through its ai\u00b2 platform and ai\u00b2 Futures Lab execution model, L\u014dkahi integrates cross-functional expertise and disciplined decision-making to drive strategic development and long-term value creation. For more information, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fprotect.checkpoint.com%2Fv2%2Fr01%2F___https%3A%2Fwww.globenewswire.com%2FTracker%3Fdata%3DQLuJnTx3A6Xswjosz5FqUzt9KWLpAhJ4x44o8hd2QYRAlDjymNnrxGab7L3KQ7Y8qX5mpnxvgEGzPgtAYjEkoxBYlC3C_OP9vlyG2oXEwmcUBygFB0dd9pPv78GY8GB-pIIYYAEzi8qRTq8YhL-ksTEC2GXVqxwTSiDPO9GpClDTf-I-niqYcpEYGP2fVF_t0ofg0i9UdvE_-NxSUj4stC4Y2OVOsDC1AENTEigrlgqe3JbBJKIEkes6BepKGVCB4elRMMLlDCA0ggpy6LQ0aexduHRp7MXWDK001V5Ow8w37eJ35Mr-ZrNg3HzQOh3t8tZ9fy3Vs9vrw72KG9YT9D99Hl6GJa9CNkONOVatdsScGvIUOJu9Q2k0pl2Wb0EjBgJpEyzm6GuLAO_W_I4lLeAjcSPYgYX2SVnrdvULksB3Lcfq-QDr23aoa5KfGUbwcD5bJn8eSuYtGXl8U0IPIg%3D%3D___.YXAzOmxva2FoaXRoZXJhLWNvbS01NWU3ZDA0ZDpjOm9mZmljZTM2NV9lbWFpbHNfYXR0YWNobWVudDo0NWE0YmI1ZDI5YjA5M2UwYWM1ZDJkYjhlNTk0MGMwNzo3OjY0YTk6ODg0Yzg4ODkyNGFlN2JhMGZiNTA2NWJlODUzYzUxNzRlZDllN2FkMzM0MGFjNTk5OTQ0Y2Y3YTI5NzkzM2ExNDpwOlQ6Rg&amp;esheet=54602003&amp;newsitemid=20260911828722&amp;lan=en-US&amp;anchor=www.lokahithera.com&amp;index=2&amp;md5=cdd05101b488ae0b017e85e4dc42dd29\">www.lokahithera.com<\/a>. For more information on the ai\u00b2 division, please visit <a rel=\"nofollow\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.ai2equals.com&amp;esheet=54602003&amp;newsitemid=20260911828722&amp;lan=en-US&amp;anchor=www.ai2equals.com&amp;index=3&amp;md5=b11edb28861a54dbb24cb7a4351d2067\">www.ai2equals.com<\/a>.<\/p>\n<p><b>Forward-Looking Statements<\/b><\/p>\n<p>\nThis news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as &#8220;anticipate&#8221;, &#8220;believe&#8221;, &#8220;expect&#8221;, &#8220;plan,&#8221; and &#8220;will&#8221; are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Glucotrack undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Glucotrack will be realized or, even if substantially realized, that they will have the expected consequences to or effects on us or our business or operations. Readers are cautioned that certain important factors may affect Glucotrack&#8217;s actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect Glucotrack&#8217;s results include, but are not limited to, the ability of Glucotrack to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to merger integration; risks relating to the receipt (and timing) of regulatory approvals (including U.S. Food and Drug Administration approval); risks relating to enrollment of patients in, and the conduct of, clinical trials; risks relating to Glucotrack&#8217;s future distribution agreements; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Glucotrack&#8217;s filings with the U.S. Securities and Exchange Commission (the &#8220;SEC&#8221;), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on March 30, 2026.<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20260911828722\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20260911828722\/en\/<\/a><\/span><\/p>\n<p><b>Glucotrack<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:GlucotrackPR@icrinc.com\">GlucotrackPR@icrinc.com<\/a><\/p>\n<p><b>L\u014dkahi Therapeutics\u2122<br \/>\n<\/b><br \/><a rel=\"nofollow\" href=\"mailto:ir@lokahithera.com\">ir@lokahithera.com<\/a><\/p>\n<p><b>KEYWORDS:<\/b> California New Jersey United States North America<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Biotechnology Diabetes Health Medical Devices<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260911828722\/en\/2897214\/3\/Glucotrack_logo.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>Glucotrack Announces $11.5 Million Financing RUTHERFORD, N.J. &amp; LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; Glucotrack, Inc. (NASDAQ: GCTK) (\u201cGlucotrack\u201d or the \u201cCompany\u201d) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount. The financing is structured as convertible debt with an initial conversion price of $3.12 per share. In connection with the financing, investors will also receive warrants exercisable at $7.50 per share. Dawson James Securities, Inc. acted as Sole Placement Agent for Glucotrack. About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) operates L\u014dkahi and, through its subsidiary &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Glucotrack Announces $11.5 Million Financing&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-1002899","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Glucotrack Announces $11.5 Million Financing - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Glucotrack Announces $11.5 Million Financing - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Glucotrack Announces $11.5 Million Financing RUTHERFORD, N.J. &amp; LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; Glucotrack, Inc. (NASDAQ: GCTK) (\u201cGlucotrack\u201d or the \u201cCompany\u201d) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount. The financing is structured as convertible debt with an initial conversion price of $3.12 per share. In connection with the financing, investors will also receive warrants exercisable at $7.50 per share. Dawson James Securities, Inc. acted as Sole Placement Agent for Glucotrack. About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) operates L\u014dkahi and, through its subsidiary &hellip; Continue reading &quot;Glucotrack Announces $11.5 Million Financing&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-11T12:14:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Glucotrack Announces $11.5 Million Financing\",\"datePublished\":\"2026-09-11T12:14:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/\"},\"wordCount\":631,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/\",\"name\":\"Glucotrack Announces $11.5 Million Financing - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2026-09-11T12:14:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/glucotrack-announces-11-5-million-financing\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Glucotrack Announces $11.5 Million Financing\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Glucotrack Announces $11.5 Million Financing - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/","og_locale":"en_US","og_type":"article","og_title":"Glucotrack Announces $11.5 Million Financing - Market Newsdesk","og_description":"Glucotrack Announces $11.5 Million Financing RUTHERFORD, N.J. &amp; LA JOLLA, Calif.&#8211;(BUSINESS WIRE)&#8211; Glucotrack, Inc. (NASDAQ: GCTK) (\u201cGlucotrack\u201d or the \u201cCompany\u201d) today announced definitive agreements for convertible notes with an aggregate principal amount of approximately $11.5 million, including approximately $4.5 million of new cash investment and approximately $4.5 million of existing notes being rolled over, with the aggregate principal amount reflecting a 22% original issue discount. The financing is structured as convertible debt with an initial conversion price of $3.12 per share. In connection with the financing, investors will also receive warrants exercisable at $7.50 per share. Dawson James Securities, Inc. acted as Sole Placement Agent for Glucotrack. About Glucotrack, Inc. Glucotrack, Inc. (NASDAQ: GCTK) operates L\u014dkahi and, through its subsidiary &hellip; Continue reading \"Glucotrack Announces $11.5 Million Financing\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/","og_site_name":"Market Newsdesk","article_published_time":"2026-09-11T12:14:51+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Glucotrack Announces $11.5 Million Financing","datePublished":"2026-09-11T12:14:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/"},"wordCount":631,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/","name":"Glucotrack Announces $11.5 Million Financing - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2026-09-11T12:14:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20260911828722r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/glucotrack-announces-11-5-million-financing\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Glucotrack Announces $11.5 Million Financing"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002899","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=1002899"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/1002899\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=1002899"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=1002899"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=1002899"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}